Related Experiment Video
Updated: Jan 3, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Clinical Commissioning of a Pencil Beam Scanning Treatment Planning System for Proton Therapy
Jatinder Saini1, Ning Cao2, Stephen R Bowen2,3
1Seattle Cancer Care Alliance Proton Therapy Center, Seattle, WA, USA.
Purpose:
In this report, we present the commissioning and validation results for a commercial proton pencil beam scanning RayStation treatment planning system.
Materials And Methods:
The commissioning data requirements are (1) integrated depth dose curves, (2) spot profiles, (3) absolute dose/monitor unit calibration, and (4) virtual source position. An 8-cm parallel plate chamber was used to measure the integrated depth dose curves by scanning a beam composed of a single spot in a water phantom. The spot profiles were measured at 5 different planes using a 2-dimensional scintillation detector. The absolute dose/monitor unit calibration was based on dose measurements in single-layer fields of size 10 × 10 cm2. The virtual-source position was calculated from the change in spot spacing with the distance from the isocenter. The beam model validation consisted of a comparison against commissioning data as well as a new set of verification measurements. For end-to-end testing, a series of phantom plans were created. These plans were measured at 1 to 3 depths using a 2-dimensional ion chamber array and evaluated for gamma index using the 3% and 3 mm criteria.
Results:
The maximum deviation for spot sigma measured versus calculated was -0.2 mm. The point-dose measurements for single-layer beams were within ± 3%, except for the largest field size (29 × 29 cm2) and the highest energy (226 MeV). The point doses in the spread-out Bragg peak plans showed a trend in which differences > 3% were seen for ranges > 30 cm, field sizes > 15 × 15 cm2, and depths > 25 cm. For end-to-end testing, 34 planes corresponding to 13 beams were analyzed for gamma index with a minimum pass rate of 92.8%.
Conclusion:
The acceptable verification results and successful end-to-end testing ensured that all components of the treatment planning system were functional and the system was ready for clinical use.

